[HTML][HTML] NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22

MR Spalinger, S Kasper, C Gottier… - The Journal of …, 2016 - Am Soc Clin Investig
MR Spalinger, S Kasper, C Gottier, S Lang, K Atrott, SR Vavricka, S Scharl, PM Gutte…
The Journal of clinical investigation, 2016Am Soc Clin Investig
Inflammasomes form as the result of the intracellular presence of danger-associated
molecular patterns and mediate the release of active IL-1β, which influences a variety of
inflammatory responses. Excessive inflammasome activation results in severe inflammatory
conditions, but physiological IL-1β secretion is necessary for intestinal homeostasis. Here,
we have described a mechanism of NLRP3 inflammasome regulation by tyrosine
phosphorylation of NLRP3 at Tyr861. We demonstrated that protein tyrosine phosphatase …
Inflammasomes form as the result of the intracellular presence of danger-associated molecular patterns and mediate the release of active IL-1β, which influences a variety of inflammatory responses. Excessive inflammasome activation results in severe inflammatory conditions, but physiological IL-1β secretion is necessary for intestinal homeostasis. Here, we have described a mechanism of NLRP3 inflammasome regulation by tyrosine phosphorylation of NLRP3 at Tyr861. We demonstrated that protein tyrosine phosphatase non-receptor 22 (PTPN22), variants in which are associated with chronic inflammatory disorders, dephosphorylates NLRP3 upon inflammasome induction, allowing efficient NLRP3 activation and subsequent IL-1β release. In murine models, PTPN22 deficiency resulted in pronounced colitis, increased NLRP3 phosphorylation, but reduced levels of mature IL-1β. Conversely, patients with inflammatory bowel disease (IBD) that carried an autoimmunity-associated PTPN22 variant had increased IL-1β levels. Together, our results identify tyrosine phosphorylation as an important regulatory mechanism for NLRP3 that prevents aberrant inflammasome activation.
The Journal of Clinical Investigation